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A B S T R A C T
The Resistin-Like Molecules (RELM) α, β, and γ and their namesake, resistin, share structural and sequence
homology but exhibit signiﬁcant diversity in expression and function within their mammalian host. RELM
proteins are expressed in a wide range of diseases, such as: microbial infections (eg. bacterial and helminth),
inﬂammatory diseases (eg. asthma, ﬁbrosis) and metabolic disorders (eg. diabetes). While the expression pattern
and molecular regulation of RELM proteins are well characterized, much controversy remains over their pro-
posed functions, with evidence of host-protective and pathogenic roles. Moreover, the receptors for RELM
proteins are unclear, although three receptors for resistin, decorin, adenylyl cyclase-associated protein 1 (CAP1),
and Toll-like Receptor 4 (TLR4) have recently been proposed. In this review, we will ﬁrst summarize the mo-
lecular regulation of the RELM gene family, including transcription regulation and tissue expression in humans
and mouse disease models. Second, we will outline the function and receptor-mediated signaling associated with
RELM proteins. Finally, we will discuss recent studies suggesting that, despite early misconceptions that these
proteins are pathogenic, RELM proteins have a more nuanced and potentially beneﬁcial role for the host in
certain disease settings.
1. Introduction
Resistin-like molecules (RELMs) are mammalian secreted proteins,
which were identiﬁed less than 20 years ago in diﬀerent disease set-
tings, leading to diﬀering nomenclature [1–6]. RELMα (Retnla) was the
ﬁrst RELM protein discovered in a mouse model of asthma, where it was
named FIZZ1 for Found in Inﬂammatory Zone. Murine resistin (Retn/
FIZZ3) was subsequently identiﬁed and functionally characterized in
metabolic dysfunction, where it caused “resistance” to insulin, leading
to the more common nomenclature for this protein family as ‘RELMs’.
Finally, RELMα was also investigated in hypoxia and named Hypoxia-
Induced Mitogenic Factor (HIMF) [1]. The complex nomenclature de-
monstrates signiﬁcant diversity in RELM expression pattern and func-
tion, however, it may cause confusion and potential bias when
searching for studies on this intriguing family of proteins. Here, we
provide a comprehensive summary of the RELM/FIZZ/HIMF protein
family, from their discovery to more recent studies elucidating their
function and putative receptors.
We will focus on the three main research areas in which RELM
proteins were discovered, which include microbial infection, in-
ﬂammatory diseases and metabolic dysfunction. In addition, we will
highlight the existing controversies over the pathogenic versus
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protective function for these proteins. While early studies proposed
detrimental roles for RELM proteins due to their abundant expression in
pathologic settings, more recent studies suggest that these proteins can
provide beneﬁcial functions from improving metabolic homeostasis to
reducing inﬂammation and promoting wound healing. Here, we revisit
the literature on RELM proteins to (i) consolidate what is known re-
garding RELM genetic regulation and signaling; and (ii) delineate the
function of each RELM in various disease states. We hope to highlight
the versatility of these proteins and the signiﬁcant role they play in host
physiology. Only by fully understanding RELMs in their respective roles
within their host, can we make informed decisions on the possibility of
targeting these molecules and downstream pathways for new therapies
in infection, inﬂammation and metabolic dysfunction.
2. Molecular regulation of RELM genes
2.1. RELM gene and protein structure
The RELM gene family (Retn) was originally identiﬁed in mice, but
appears to be present in all mammals [2]. While mice and rats have four
RELM genes Retn, Retnla, Retnlb, Retnlg; only Retn and Retnlb belong to a
diverse taxonomic group, including humans, nonhuman primates, ca-
nines, cats and horses. In mice and rats, three of the four RELM genes,
Retnlb, Retlna and Retnlg, are clustered together on chromosome 16 [3].
These genes share the most sequence homology and exhibit similar
transcriptional regulation, but are diﬀerentially expressed in cell-types
and tissue. In comparison, mouse Retn, human Retn and human Retnlb
exhibit greater diversity in transcriptional regulation and expression
pattern, and are present on diﬀerent chromosomes (chromosomes 8, 19
and 3 respectively). Sequence identity is high between human and
mouse RELM proteins, with ∼60% homology in amino acid sequence
[4,5]. Fig. 1 summarizes the gene expression proﬁle and transcriptional
regulation of mouse and human RELM genes.
RELM genes encode secreted proteins of 105–138 amino acids in
size with 3 main domains: an amino (N) terminal signal sequence, a
variable middle section, and a conserved carboxyl (C) terminal. The C
terminal is comprised of a cysteine signature motif sequence shared by
all RELM family members (C-X11-C-X8-C-X-C-X3-C-X10-C-X-C-X-C-X9-
CC-X3–6-END), which is proposed to be critical for disulﬁde bond for-
mation and protein folding [3,6,7]. The crystal structures of mouse
resistin and RELMβ have been solved, revealing that they form trimers
linked together via disulﬁde bonds to form hexameric assemblies [8].
Dimerization of RELMβ and resistin was dependent on a cysteine in the
N-terminal. This cysteine is lacking in RELMα and RELMγ, suggesting
that they may exist as monomers [9,10], however their crystal structure
has not been solved. A better understanding of the RELM protein
structure may provide important information for identiﬁcation of the
receptors, which remain unknown for many of the RELM proteins.
2.2. Genetic regulation of RELM expression
The genetic regulation and expression proﬁle of the RELM genes
have been well characterized from several human and murine studies
(Fig. 1A). These studies reveal both shared and distinct cellular ex-
pression proﬁles within the RELM gene family (Fig. 1B). While some
RELM genes, such as RELMα, RELMγ and human resistin, are expressed
by hematopoietic cells, mouse resistin, RELMα and RELMβ are ex-
pressed in non-hematopoietic cells. All mouse and human RELM pro-
teins are detectable in the serum, oﬀering the potential to utilize RELM
levels as biomarkers [11–13]. In this section, we summarize what is
known about the cellular expression of RELM genes, the disease settings
in which they are expressed, and how they are transcriptionally regu-
lated.
2.2.1. RELMα
RELMα/Retnla exhibits the greatest heterogeneity in expression
within the RELM family. Under homeostatic conditions, RetnlamRNA is
present at low levels in the lung, tongue, mammary tissue, and white
adipose tissue [6]. Originally discovered as a secreted protein in the
bronchio-alveolar lavage of ovalbumin-challenged mice, the consensus
from multiple studies using mouse asthma models is that RELMα is
highly expressed by airway epithelial cells and type 2 pneumocytes
[1,14,15]. Consistent with this, RELMα transcription is driven and
critically dependent on a T helper type 2 (Th2) cytokine environment.
Indeed, binding sites for the Th2 cytokine-induced transcription factor
STAT6 are present within the Retnla promoter, and STAT6−/− or IL-
Fig. 1. RELM expression in mouse and man.
(A) Genetic regulation and chromosome lo-
cation of the human and murine RELM
genes. Dashed arrows represent putative
transcriptional regulation, while solid ar-
rows represent molecularly conﬁrmed tran-
scription factors. (B) Phylogenetic tree il-
lustrating the relatedness of mouse and
human RELMs was generated using http://
www.phylogeny.fr software. Bootstrap va-
lues are indicated in red. The primary cell
types that express each RELM are presented.
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4−/− mice exhibit reduced RELMα expression [16,17]. In addition to
expression by non-hematopoeitc cells, RELMα is also recognized as a
key signature gene of M2/alternatively activated macrophages that
diﬀerentiate in chronic, Th2 cytokine-skewed conditions such as hel-
minth or chronic protozoan parasite infection [17–20]. RELMα ex-
pression by other immune cells, eosinophils and dendritic cells, has also
been reported [18,21]. RELMα is also expressed in lung and peritoneal
injury models, and following hypoxic stress [1,22,23]. In these models,
RELMα expression may rely on other transcription factors, such as
CCAAT/enhancer-binding protein (C/EBP), which binds to its’ speciﬁc
motif adjacent to the STAT6 binding site in the Retnla promoter [16].
While RELMα induction can occur in the absence of Th2 cytokine sig-
naling, likely through C/EBP, sustained RELMα expression requires Th2
cytokine stimulation [23]. Interestingly, functional transcription stu-
dies revealed that C/EBP binding to the Retnla promoter was necessary
for IL-4/STAT6-induced Retnla expression, suggesting that the STAT6
and C/EBP work in tandem to activate the Retnla gene [16]. There are
also putative binding sites for Ets family proteins and PPAR, upstream
and downstream of the STAT6 binding site respectively [16]. Further-
more, transcription factor binding motifs for NF-κB, GAS, and C/EBP
are present throughout the Retnla gene, both in the 5′ and 3′ ﬂanking
regions and in introns [1].
2.2.2. RELMβ
The RELMβ/Retnlb expression pattern in mouse and human studies
suggests predominant expression in the secretory granules of intestinal
goblet cells, however, expression by lung epithelial cells in asthmatic
patients and mouse models of lung ﬁbrosis is also observed [24,25].
Similar to its adjacent gene Retnla, the Retnlb promoter contains STAT6
binding sites and expression is highly induced by Th2 cytokines in vivo
in the lung and intestine, and in mouse and intestinal epithelial cell
lines [9,26,27]. In addition to regulation by Th2 cytokines, Retnlb is
also expressed in several intestinal colitis models driven by Th1/Th17
cytokines [28,29]. Additionally, bacterial colonization or lipopoly-
saccharide (LPS) alone can induce RELMβ expression through the
transcription factor Cdx2 [9,30]. Expression in these inﬂammatory
settings is likely through NFκB activation, given the predicted NFκB
binding sites within the Retnlb promoter. Both the human and mouse
Retnlb promoters also contain functional binding sites for the hepato-
cyte nuclear factor 4α (HNF4α), a transcription factor expressed in the
liver, kidney, and intestine. Indeed, in a mouse colitis model, over-
expression of the HNF4α P2 isoform promoted RELMβ expression and
inﬂammation [31]. In addition to recent studies highlighting the
functional signiﬁcance of HNF4α in intestinal inﬂammation and cancer,
HNF4α is a master regulator of liver function and metabolism [32,33].
Future studies understanding whether RELMβ is a downstream eﬀector
of HNF4α may reveal new pathologic pathways in intestinal and me-
tabolic disease.
2.2.3. Resistin
The Resistin/Retn gene exhibits an intriguing dichotomy in expres-
sion pattern between mouse and man, with expression of mouse Retn
almost exclusively by murine adipocytes, leading to its alternative
name ‘ADSF’ for adipocyte secreted factor [34]. In contrast, human Retn
is expressed by immune cells, speciﬁcally macrophages, monocytes and
neutrophils [13]. The mouse Retn gene is considerably larger than the
human Retn gene and includes a 2279 bp long intron (intron X), with
putative transcription factor binding sites: AP1, NF-κB, IRF1, IRF2,
HNF3, C/EBP, and a PPAR/RXR heterodimer binding sited called IntX-
PPRE [5]. The PPAR/RXR-like protein factors, which are found in dif-
ferentiated adipocytes, can bind to the PPRE sequence within the mouse
Retn gene [5]. This suggests that intron X could be responsible for the
adipocyte tissue speciﬁc expression of Retn in mice but not in humans,
which lack intron X.
The disparity in introns within the mouse and human Retn genes
could explain why their expression is regulated diﬀerently. For
example, TNFα decreased Retn expression in mouse adipocytes but in-
creased Retn expression human monocytes [35,36]. In contrast, high
glucose upregulated both mouse and human Retn gene expression,
while insulin treatment suppressed Retn expression in murine adipo-
cytes and human monocyte cell lines, respectively [35,37]. The high
glucose eﬀect was abrogated upon inhibition of MAPKs and NFκB,
suggesting their roles in regulating Retn expression [37]. Further, si-
milar to the mouse locus, the human Retn gene contains adipogenic
transcription factor C/EBPα binding sites [38,39]. Additionally, the
human Retn promoter has a putative binding site for adipocyte de-
termination and diﬀerentiation-dependent factor 1 (ADD1)/sterol reg-
ulatory element binding protein 1c (SREBP1c) [39]. In mice, binding of
C/EBPα to the Retn promoter was associated with recruitment of
coactivators CREB-binding protein and p300 and abundant acetylation
of histones. In this setting, PPARγ ligands were able to inhibit mouse
Retn expression, likely through inhibition of C/EBPα associated acet-
ylation [38].
Single nucleotide polymorphisms of the human Retn gene have been
investigated and are correlated with Retn gene expression associated
with metabolic diseases such as obesity and diabetes. In a Japanese
population, SNP−638 G > A and−420C > G resulted in an increase
in serum resistin levels [40,41]. This result was partially reproduced in
a Korean population that associated SNP −420C > G and the
−537A > C with signiﬁcantly higher plasma resistin levels [42]. At
the -420 SNP, stimulatory proteins (Sp) 1 and 3 preferentially bound
the −420G over -420C, and could be involved in increasing Retn ex-
pression under hyperglycemic conditions [43]. Additionally, Retn SNP
-358 with AG or at least 1 A allele is linked to higher risk of lung cancer
than wild-type (GG) carriers in a Chinese Han population [44]. The
evidence that polymorphisms may regulate human Retn expression is
adding to the growing interest in human resistin for its role in immune
and metabolic dysregulation. Further analyses on larger and more di-
verse populations will add to the current knowledge on human resistin
expression and function.
2.2.4. RELMγ
RELMγ/Retnlg is by far the least studied RELM protein. It is most
highly expressed in the hematopoietic system, with high expression in
the bone marrow, and lower expression in white blood cells, spleen and
thymus [3,7]. While RELMγ is also expressed in the lungs and the
adipose tissue, its expression is signiﬁcantly lower than RELMα [3].
RELMγ has been found to have a proliferative eﬀect on HL60 cells, but
did not have an eﬀect on cellular diﬀerentiation [7]. The genetic reg-
ulation of Retnlg expression has not yet been thoroughly examined.
3. RELM putative receptors and downstream signaling
RELMs have been studied and implicated in diverse physiological
functions. Surprisingly however, the RELM receptors and downstream
signaling pathways are largely elusive. Of the four RELMs, resistin is the
only member thus far with a conﬁrmed receptor, whereas the rest of the
members are associated with putative or unknown receptors. Fig. 2
summarizes our current understanding of RELM protein signaling and
function.
3.1. RELMα
Although extensively studied, the search for a RELMα receptor still
continues (Fig. 2A). RELMα binding assays revealed that it selectively
binds to CD4+ Th2 cells, dendritic cells and macrophages [45]. There is
evidence that Bruton’s tyrosine kinase (BTK), an important signaling
molecule in B cell maturation, is a binding partner for RELMα [45,46]
(Fig. 2A, I). Immunoﬂuorescent assays have shown that upon RELMα
stimulation, BTK redistributes and anchors to the cell membrane where
it then co-localizes with RELMα [46]. Given that BTK is an intracellular
protein, the exact interaction between the secreted extracellular RELMα
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and intracellular BTK is unclear. Two distinct outcomes of RELMα
binding associated with BTK signaling have been reported. First,
RELMα induced BTK autophosphorylation and stimulated myeloid cell
chemotaxis. Second, in an in vitro CD4+ Th2 cell diﬀerentiation assay,
RELMα downregulated Th2 cytokine production in a BTK-dependent
manner [45,46].
Several in vitro studies demonstrated a chemotactic and mitogenic
function of RELMα, positing a function for RELMα in angiogenesis and
tissue remodeling (Fig. 2A, II). In human pulmonary artery smooth
muscle cells, RELMα increased intracellular Ca2+ concentrations by
activating inositol 1,4,5-triphosphate receptor (IP3R) in a phospholi-
pase C dependent mechanism [47]. RELMα also stimulated prolifera-
tion of rat pulmonary microvascular smooth muscle cells via the PI3K/
AKT signaling pathway, and induced expression of angiogenesis med-
iators: VEGF and MCP-1, and monocyte recruiting chemokine SDF-1x
[1,48]. In a lung ﬁbrosis model, RELMα was implicated in myoﬁbro-
blast diﬀerentiation during lung ﬁbrosis, likely through activation of
Notch1 and Jagged1 [49]. While ﬁbroblast activation is detrimental in
pulmonary or liver ﬁbrosis, it is a required wound healing process
following tissue injury. Recent evidence supports a critical function for
RELMα in wound healing through ﬁbroblast activation. Following skin
excision wounds in mice, RELMα induced ﬁbroblast expression of lysyl
hydrolase 2, an enzyme that mediates collagen cross-linking for skin
repair and tissue regeneration [50–52]. Finally, RELMα also acts as an
adipokine to regulate metabolic homeostasis [53]. RELMα increased
expression of cholesterol-7-α-hydroxylase (Cyp7a1) in hepatocytes by
inducing the transcriptional activator liver receptor homologue-1 (LRH-
1). This eﬀect was beneﬁcial in hyperlipidemic mice as it promoted
excretion of cholesterol in the form of bile acids (Fig. 2A, III).
3.2. RELMβ
Similar to RELMα, RELMβ promotes cell proliferation, but has no
identiﬁed receptor. In human diabetic nephropathy mesangial cells,
RELMβ induced phosphorylation of p38MAPK and JNK, and cell pro-
liferation (Fig. 2B, I) [54]. In contrast to RELMα, RELMβ contributed to
metabolic dysfunction by signaling though MAPK pathways and sup-
pressing insulin signaling in hepatocytes (Fig. 2B, II-III). While RELMα
binds host cells, murine RELMβ can bind the pore-like structures in the
chemosensory apparatus of helminths Trichuris muris and Strongyloides
stercoralis, where it inhibited helminth chemotaxis and feeding [55,56].
Consistent with an anti-microbial function for RELMβ, a recent study
showed that both mouse and human RELMβ, and human resistin, could
bind gram negative bacteria and permeabilize their membranes [57].
Therefore, while the mechanism of action of RELMα is on the host,
RELMβ may act both on the host and the pathogen. It is unclear whe-
ther the receptors for these proteins, spanning host and microbe, are
similar, however, information from one organism may help guide
identiﬁcation of the receptors in others.
3.3. Resistin
In contrast to RELMα and RELMβ, mouse and human resistin re-
ceptors and downstream signaling are better characterized. In adipose
stromal cells (ASC), mouse resistin bound to an isoform of decorin
(DCN) with functional eﬀects on cell proliferation and migration
(Fig. 2C, I) [58]. On the other hand, human resistin binds Toll-like
Receptor 4 (TLR4), the innate receptor for LPS (Fig. 2C, II). Human
resistin signaling via TLR4 inhibited LPS binding and function and fatal
endotoxic shock in a mouse sepsis model [59,60]. This protective
function of resistin can be attributed to a switch from pro-inﬂammatory
(NFκB) to anti-inﬂammatory signaling pathways (TRIF/TBK-1 and
STAT3) [60]. Since TLR4 signaling through Myd88/NFκB is distinct
from JAK-STAT3 signaling, human resistin-TLR4 stimulation of STAT3
signaling could be indirect, perhaps through induction of IL-10. While
human resistin may be anti-inﬂammatory in response to a fatal en-
dotoxin challenge, other studies have shown that human resistin alone
can promote inﬂammation [61]. These conﬂicting ﬁndings suggest that
the resulting pro-inﬂammatory or anti-inﬂammatory function of resistin
is context and disease-speciﬁc. In colon cancer studies, resistin signaling
through TLR4 receptor was described to increase TLR4-MyD88 sig-
naling and SOCS3 expression [62]. The ensuing inhibition of JAK2/
STAT3 signaling caused arrest of colon cell growth suggesting that re-
sistin signaling through TLR4 could delay cancer progression [62].
Although LPS is the most recognized ligand for TLR4, human resistin is
not the only alternate ligand for TLR4. Indeed, TLR4 is reported to bind
saturated fatty acids, the dust mite allergen Derp2, helminth antigens,
the host endogenous protein high mobility group box 1 (HMGB) and
heat shock proteins [63–68]. Alternate ligands for other TLRs is ob-
served, and suggests that the evolution of TLR signaling and function
was likely inﬂuenced by both microbial ligand and host endogenous
molecules. Whether inﬂammatory or cancer disease outcomes are al-
tered by these TLR4 alternate ligands in combination or alone is un-
known, but needs to be considered when evaluating their overall
function.
Adenylyl cyclase-associated protein 1 (CAP1) is also a proposed
receptor for human resistin [69] (Fig. 2C, III). In monocyte cell lines,
resistin-CAP1 interaction led to increased cAMP levels, increased PKA,
and NF-κB, and subsequent levels of inﬂammatory cytokines: IL-6,
TNFα, and IL-1β [69]. Intriguingly, CAP1 is an intracellular receptor
with no predicted transmembrane domain. Therefore, it is likely that
resistin may need to bind a surface receptor, such as TLR-4, for en-
docytosis and presentation to CAP1. Finally, human resistin has also
been described as a molecular chaperone, which binds to misfolded
proteins in the cell, protecting it from stress-induced apoptosis (Fig. 2C,
IV) [70].
Although homologous, RELMs function through various signaling
mechanisms that lead to diversiﬁed physiological phenotypes. Even
though mechanistic studies on RELMs exist, the receptors for these
Fig. 2. Proposed receptor and signaling of RELMα (A), RELMβ (B) and Resistin
(C).
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proteins remain elusive. There are also no studies investigating RELMγ
signaling. By exploring RELM signaling, it becomes evident that this
family of proteins underwent a divergence in their evolution. However,
by delving into their physiological functions, we can start to appreciate
the similarities that RELMs retained.
4. The long and winding road: RELM function in mice and men
There have been a multitude of diverse studies investigating RELM
protein function, some of which reveal opposing functions. This section
will review the functional studies on RELMs and their putative roles in
infection, inﬂammatory and autoimmune diseases and metabolic
function (summarized in Fig. 3).
4.1. Microbial infection
4.1.1. RELMα
The use of RELMα−/− mice in helminth and bacterial infection as
well as helminth antigen sensitization models has revealed complex
host immunomodulatory roles for this protein. Following infection with
the rat hookworm Nippostrongylus brasiliensis, RELMα suppressed Th2
cytokine responses through functional eﬀects on CD4+ Th2 cells, which
impaired optimal adult worm expulsion [11,45,71]. On the other hand,
RELMα’s suppression of Th2 inﬂammation had beneﬁcial eﬀects for the
host as it prevented excessive and potentially fatal lung inﬂammation.
It seems therefore that RELMα acts as a critical rheostat in the balance
between host immunity and inﬂammation, preserving host immune
homeostasis sometimes at the expense of optimal antimicrobial im-
munity. In addition to direct suppression of CD4+ Th2 cells, RELMα
was also able to promote IL-10 producing regulatory T cells following
stimulation with Schistosoma mansoni antigen-pulsed dendritic cells
[21]. In a mouse model of enteropathogenic/enterohemorrhagic bac-
terial infection with Citrobacter rodentium, RELMα-mediated suppres-
sion of Th2 cytokines led instead to increased Th17 cytokine-driven
inﬂammation in the colon. Surprisingly, RELMα immunostimulatory
eﬀect had no signiﬁcant eﬀect on bacterial clearance suggesting that
RELMα expression in Citrobacter rodentium infection was soley
detrimental to the host [29,72].
4.1.2. RELMβ
Infection studies with RELMβ−/− mice suggest that RELMβ pro-
motes immunity to helminth and bacterial pathogens. RELMβ−/− mice
were more susceptible to Heligmosomoides polygyrus and Nippostrongylus
brasiliensis but not Trichuris muris infection [11,55,56,73]. In intestinal
bacterial infection with Citrobacter rodentium, RELMβ−/− mice suc-
cumbed to infection due to mucosal ulceration and deep penetration of
the Citrobacter into the colonic crypts [74]. Mechanistic studies evalu-
ating RELMβ function suggest that RELMβ’s protective eﬀect is twofold:
(i) promoting host immune cell responses and (ii) directly killing the
pathogen. First, RELMβ promoted CD4+ T cell recruitment to the Ci-
trobacter-infected intestines and increased production of antimicrobial
cytokine IL-22 [74]. Additionally, recombinant RELMβ treatment of
macrophage and splenocyte cultures promoted Th1 immune responses,
which are protective in bacterial and viral infections, but not in chronic
helminth infection [73]. Second, RELMβ binds both helminths and
gram negative bacteria, leading to impaired helminth function and
bacterial killing, respectively [55–57]. This microbicidal role for
RELMβ is also shared by murine and human resistin.
Although not explored in the context of infection, there is strong
evidence that RELMβ shapes the host microbiome. Compared to con-
ventionally housed mice, germfree mice exhibited deﬁciency in in-
testinal RELMβ expression in the intestine that was restored upon co-
lonization with commensal bacteria [9]. This eﬀect was not entirely
recapitulated with LPS treatment, suggesting that other bacterial factors
regulate RELMβ expression [9]. However, when intestinal cell lines
were directly stimulated with LPS, there was only a modest expression
of RELMβ [9]. Between these two observations, it is likely that the
microbiome within the colon can induce the expression of RELMβ,
however, this expression was not purely driven by LPS expression and
there are likely other bacterial factors in play. Recombinant RELMβ has
antibacterial activity against gram negative bacteria, by binding to
negatively charged lipids and creating multimeric pores within the
membrane [57]. Because of this antimicrobial activity, RELMβ likely
prunes the microbial communities present within the colon. Indeed,
Fig. 3. The diverse roles of RELMs in infection, inﬂammation and metabolism.
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microbiome evaluation of wild-type and RELMβ−/− mice revealed in-
creased gram negative bacterial invasion into the colon inner mucus
layer, and increased abundance of Proteobacteria including Helicobacter
[57]. Whether RELMβ’s functional eﬀects on the bacterial and helminth
infection are in part mediated by its inﬂuence on the microbiome re-
mains to be determined.
4.1.3. Resistin
Human resistin function has been explored in helminth and viral
infections. In both chronic ﬁlarial nematode infection and intestinal
ascaris infection, plasma resistin levels were elevated and correlated
with increased parasite burden and increased inﬂammatory cytokines
TNFα, CCL2 and IL-6 [13]. The ﬁndings in these correlative studies
were validated in vivo by employing human resistin transgenic mice
[13]. Here human resistin expression led to increased Nippostrongylus
brasiliensis parasite burdens, correlated with increased TNFα and CCL2
gene expression. The eﬀect of resistin in promoting a susceptible phe-
notype to helminth infection is similar to RELMα, however, instead of
inhibiting Th2 cytokines, it seems that resistin tips the balance from a
Th2-type response to a proinﬂammatory cytokine response. Again, si-
milar to RELMα, it seems the role of resistin in helminth-infected hosts
is counterintuitive. However, it is likely that resistin exists to direct the
immune response towards combating more fatal bacterial or viral in-
fections in an environment where bacterial-worm co-infections are
common. Consistent with this, resistin has microbicidal properties and
could protect mice from fatal endotoxic shock [57,60]. Interestingly,
compared to human resistin, mouse resistin did not have an impact on
parasite burdens [13]. An explanation for this could be that human and
mouse resistin expression are regulated diﬀerently and therefore have
divergent functions in helminth infection. Mouse resistin and its role in
helminth infection, if any, has yet to be uncovered.
Patients with chronic Hepatitis B viral infection had signiﬁcantly
elevated serum resistin levels, that were increased with progression to
HBV-associated liver cirrhosis and liver failure [75]. In chronic Hepa-
titis C virus-infected patients, a correlation exists between resistin and
liver ﬁbrosis severity [76]. In patients with HCV-induced chronic he-
patitis, resistin expression was found to be higher in areas with in-
ﬂammation and ongoing ﬁbrogenisis [77]. Whether resistin is an in-
stigator of viral-induced inﬂammation or is simply a result of viral
infection is yet unclear.
4.2. Inﬂammatory and ﬁbrotic disease
As in infection, the role for RELM proteins in inﬂuencing the im-
mune response is recognized in several studies on inﬂammatory and
ﬁbrotic diseases. However, whether they play a pathogenic function in
stimulating inﬂammation, or instead protect against excessive in-
ﬂammatory responses is controversial. Some of this conﬂicting evidence
may be caused by discrepancies between correlative and functional
studies, while another contributor may be the use of endotoxin-con-
taminated bacterially-derived recombinant proteins. In addition to
these caveats, it is becoming increasingly clear that the disease context
and RELM protein level and expression pattern may be critical for their
beneﬁcial or pathologic outcomes.
4.2.1. RELMα and RELMβ
RELMα is highly expressed in lung injury and allergic airway in-
ﬂammation models, where several studies, using recombinant RELMα
administration or RELMα-expressing transgenic mice, conﬁrmed a
function in promoting chemotaxis for eosinophils and dendritic cells,
and vascular inﬂammation [48,78–80]. On the other hand, RELMα−/−
mice exhibited similar airway and lung inﬂammation compared to
wild-type mice following ovalbumin or Aspergillus-induced allergic
airway inﬂammation [81]. In another study using RELMα-over-
expressing transgenic mice, RELMα signiﬁcantly suppressed oval-
bumin-induced Th2 lung immune responses, correlated with reduced
pERK signaling [14]. This is consistent with the original studies re-
porting RELMα−/− mice, where RELMα dampened the Th2 lung in-
ﬂammatory response to sensitization and challenge with helminth
Schistosoma mansoni egg antigen [45,71].
In several studies investigating dextran sodium sulfate-induced in-
testinal inﬂammation as a mouse model of ulcerative colitis, RELMα−/
− and RELMβ−/− mice exhibited reduced intestinal pathology and
Th17 and TNFα cytokine responses compared to wild-type mice
[29,31,82,83]. In contrast, RELMβ−/− mice suﬀered from more severe
trinitrobenzene sulfonate-induced colitis, as a model for Crohn’s dis-
ease, compared to wild-type mice [83]. The functional consequence of
human RELMβ in IBD patients has yet to be determined, however, the
mouse studies suggest that RELMβ’s role may be diﬀerent depending on
the type of inﬂammatory bowel disease (ulcerative colitis versus
Crohn’s disease).
RELMα function in tissue repair and ﬁbrosis is better understood
with several studies showing that RELMα promotes these processes.
Both tissue repair and ﬁbrosis share similar pathways, such as stimu-
lation by Th2 cytokines [84]. However, tissue repair is the desired
outcome to injury while ﬁbrosis, or scarring, occurs when tissue repair
is not kept in check. Given that RELMα is stimulated by Th2 cytokines
following both lung and skin injury, it was posited that RELMα maybe
the downstream mediator of Th2 cytokine-induced tissue repair. Sup-
portive of this, RELMα promoted myoﬁbroblast diﬀerentiation and in-
creased expression of type 1 collagen and α-SMA expression, leading to
thickened ﬁbrotic dermis and extracellular matrix deposition in bleo-
mycin-induced dermal ﬁbrosis [85]. Another study using skin biopsy-
induced injury showed that IL-4 activated RELMα mediated skin
healing by controlling collagen ﬁbril assemby [50]. RELMα was proﬁ-
brotic in bleomycin-induced pulmonary ﬁbrosis through several pro-
posed mechanisms: bone marrow cell recruitment, increased expression
of VEGF, ﬁbroblast and myoﬁbroblast activation [86,87]. Similar to
RELMα, murine RELMβ also promoted bleomycin-induced pulmonary
ﬁbrosis, associated with increased lung ﬁbroblast proliferation, col-
lagen expression, and leukocyte recruitment [88]. Of clinical sig-
niﬁcance, human asthmatic patients have RELMβ deposits in the ex-
tracellular matrix associated with increased airway remodeling [24].
4.2.2. Resistin
Increased circulating levels of resistin are observed in several
human inﬂammatory diseases including endotoxemia, sepsis, rheuma-
toid arthritis and inﬂammatory bowel disease [89]. In vitro human
monocyte culture and in vivo studies with human resistin-expressing
transgenic mice suggest that resistin is a stimulatory cytokine that
promotes immune cell activation and chemotaxis, neutrophil extra-
cellular trap formation and inﬂammatory cytokine production [61,69].
More recent studies reveal that resistin may be anti-inﬂammatory in
certain contexts. Resistin could impair LPS function and protect against
high dose LPS-induced endotoxic shock [60]. Intriguingly, serum re-
sistin levels were lower in patients with myalgic encephalitis/chronic
fatigue syndrome, and was associated with reduced disease severity in
patients with moderate to severe disease [90]. More functional studies
are needed to determine the contribution of resistin to these immune-
mediated diseases.
4.3. Cancer
While there are no reports on RELMα expression or function in
cancer, human RELMβ expression was detected in 65.4% of 136 human
cases of gastric cancers, where there was a positive correlation between
RELMβ expression and patient survival [91]. Additionally, murine
RELMβ was associated with reduced susceptibility to azoxymethane
and DSS induced colorectal cancer, indicating that RELMβ could have a
protective role in cancer [92]. Mechanistically, RELMβ decreased Th2
cytokine levels, it was suggested that RELMβ may indirectly slow the
progression of colon cancer by decreasing inﬂammation [92]. In
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contrast, another study found that RELMβ overexpression in gastric
carcinoma cells signiﬁcantly increased invasion and migration of gas-
tric cancer cells in a transwell assay [93]. Thus, RELMβ expression in
gastric cancer may have a more complicated mechanism than initially
predicted.
Resistin is reported to have indirect eﬀects within inﬂammatory
cancers. As previously mentioned, resistin signaling through TLR4-ERK-
SOCS3 delays the progression of colonic cancers [62]. However, the
arrest in cell cycle led to these cancer cells being more resistant to
chemotherapeutic drugs that target highly proliferating cells. Further,
another study showed that resistin blocked the apoptotic eﬀect of the
chemotherapy drugs, bortezomib or carﬁlzomib [94]. Here, treatment
of various cancer cell lines with resistin resulted in upregulation of the
transporter genes ABCC5, and ABCG2, that could act to export the
drugs outside the cells [94]. In conclusion, it seems that both RELMβ
and resistin are protective in inhibiting cancer progression, but may
interfere with chemotherapy.
4.4. Metabolic function
4.4.1. RELMα and RELMβ
RELMα expression is observed within white adipose tissue of high
fat diet-fed mice [53]. RELMα deﬁciency in hyperlipidemic and
atherosclerotic mice resulted in signiﬁcant cholesterol increase, while
overexpression of RELMα resulted in the reverse eﬀect [53]. Mechan-
istically, RELMα overexpression upregulated the liver cholesterol
catabolic enzymes, Cyp7a1 and Cyp8b1, which are responsible for
breaking down cholesterol and converting it to bile acid. Consistent
with this, RELMα overexpressing mice had increased fecal bile acid
content and fecal cholesterol indicating a RELMα-mediated mechanism
for cholesterol breakdown and clearance. RELMα thus induces deple-
tion and clearance of cholesterol, and further implies that RELMα has
beneﬁcial functions in metabolism. However, in another study, RELMα
expressed by CD301b+ mononuclear phagocytes within the white
adipose tissue was important in maintaining healthy body weight and
glucose levels [95]. When CD301b+ mononuclear phagocytes were
depleted, there was a signiﬁcant downregulation of metabolic genes in
the liver, associated with hyperglycemia. This eﬀect was reversed when
the mice were exogenously treated with recombinant RELMα. In con-
trast, another study reported that RELMα−/−mice were protected from
hyperglycemia [96]. It is possible that these discrepancies reﬂect dif-
ferences in cell-speciﬁc deletion of CD301b+ cells compared to whole
body RELMα−/− mice.
It is now well recognized that the immune environment, particularly
the Th1/Th2 cytokine balance, is an important contributor to metabolic
homeostasis or disease [97]. Given that RELMα is expressed by M2
macrophages, and regulates Th2 cytokines, it is possible that RELMα’s
eﬀect in metabolism is partly mediated through its immunoregulatory
function. For example, brown adipose tissue in lean mice is more
heavily populated with cells such as M2 Macs and Tregs as well as IL-4,
IL-13 and IL-10 cytokines resulting in an overall Th2 immune state that
maintains a noninﬂammatory mileu [98]. In contrast, chronically in-
ﬂamed white adipose tissue associated with obesity and insulin re-
sistance is populated with eﬀector M1 macrophages that primarily
contribute to a proinﬂammatory IL-1β, TNF-α and IL-6-rich environ-
ment [98]. In contrast to RELMα, however, resistin is associated with
proinﬂammatory macrophage activation in obesity, but recent studies
suggest that resistin can be anti-inﬂammatory in certain disease con-
texts [60]. More speciﬁc studies investigating the immune eﬀects of the
speciﬁc RELM proteins in obesity and diabetes are necessary, however,
the current data may support a therapeutic beneﬁt in employing RELM
proteins to modulate the Th1/Th2 balance to treat metabolic dysfunc-
tion.
RELMβ is highly expressed in mice fed a high fat diet [99] and
RELMβ−/− mice exhibited reduced glucose tolerance [92]. In contrast,
transgenic mice overexpressing RELMβ in hepatocytes suﬀered from
increased hyperglycemia, hyperlipidemia, fatty liver, and pancreatic
islet enlargement when fed a high fat diet [100]. Further, recombinant
RELMβ treatment suppressed insulin signaling in cultured hepatocytes,
associated with increased MAPK and reduced IRS1/2 proteins [100].
These studies suggest that, similar to RELMα, RELMβ’s eﬀect on glucose
tolerance and insulin signaling is dependent on the in vivo context and
RELMβ level. Indeed, high RELMβ levels in the liver cause metabolic
dysfunction, however, complete abrogation of RELMβ expression is also
detrimental.
4.4.2. Resistin
Resistin’s function in metabolism has been explored thoroughly, and
is discussed in a number of recent review articles [89,101,102]. The
general consensus in mouse and human studies is that resistin plays a
pathologic role in promoting insulin resistance, atherosclerosis and
hypertension. Here we will focus on a few select studies investigating
resistin in metabolic disease. In mice, inhibition or genetic deletion of
resistin resulted in increased insulin sensitivity and glucose homeostasis
[103]. Conversely administration of exogenous resistin, or transgenic
expression of human resistin, promoted insulin resistance [103–106].
Some population studies have reported an association between circu-
lating resistin levels and adiposity or increased insulin resistance [41],
but other studies have challenged this link [107–109]. A bigger dataset,
and more focused analysis parameters or exclusion criteria to reduce
confounding factors, may address human resistin’s metabolic function.
Both human and mouse resistin reduced insulin-induced glucose uptake
within cardiomyocyte cells, most likely by impairing insulin-mediated
GLUT4 translocation [110]. Further, in patients with coronary artery
disease, elevated resistin levels were correlated with aortic stiﬀness
[111]. It was hypothesized that resistin’s induction of insulin resistance
changes glucose metabolism, which causes stress to the heart when it
shifts to glucose as its energy source, and leads to heart failure. If this
theory is conﬁrmed, resistin management may prove to be a viable
option for preventive treatment in patients with cardiac disorders.
Given that resistin is an immunomodulatory molecule secreted by im-
mune cells, resistin’s cross-talk with the immune system is a likely
contributor to its’ metabolic eﬀect.
5. Concluding remarks and perspective
Whether resistin and the RELM proteins are helpful or detrimental
for the host is still under debate, however, this review has highlighted
the complexity in interaction and function of these proteins, which
suggests that their role cannot purely be deﬁned as “positive” or “ne-
gative”. For example, RELMα’s chemotactic and proliferative properties
may lead to inﬂammation but is beneﬁcial in wound healing, which
requires immune contribution. Further, RELM proteins may have
therapeutic potential. For instance, RELMα and resistin’s ability to at-
tenuate excessive inﬂammatory responses may be valuable in clinical
settings. Conversely, RELMβ and resistin’s microbicidal properties
could be harnessed as new antimicrobial agents against bacteria and
helminths. Likewise, RELMβ’s inhibitory eﬀect on cancer cell pro-
liferation and its association with improved survival could be in-
vestigated as a potential biomarker or therapy. Last, RELMα’s beneﬁcial
eﬀect in metabolic homeostasis could be explored to target metabolic
disease.
While we have attempted to comprehensively address key studies
investigating RELM protein expression and function at both the mole-
cular and whole body level, we also highlight missing or conﬂicting
information. First, research on the receptors and activation mechanisms
for these proteins is incomplete. Second, given that RELM proteins
seemingly inﬂuence metabolic, immune and microbial systems, more
multidisciplinary research to understand how eﬀects in one system may
have outcomes in another system may shed light on the conﬂicting
information in the ﬁeld. It is also possible that the eﬀects of RELM
proteins are more nuanced, and overexpression or whole body
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knockout data represent extremes in the spectrum of RELM function.
Instead, experiments investigating varied concentrations or cell-speciﬁc
expression of these proteins could be useful to examine their potential
as biomarkers or therapeutics. While we have come a long way in re-
search of resistin and resistin-like molecules, there is still much work to
do.
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